"Protozoan Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Suspensions of attenuated or killed protozoa administered for the prevention or treatment of infectious protozoan disease.
| Descriptor ID |
D016052
|
| MeSH Number(s) |
D20.215.894.582
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protozoan Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Protozoan Vaccines".
This graph shows the total number of publications written about "Protozoan Vaccines" by people in this website by year, and whether "Protozoan Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protozoan Vaccines" by people in Profiles.
-
Hung CY, Zhang H, Castro-Lopez N, Ostroff GR, Khoshlenar P, Abraham A, Cole GT, Negron A, Forsthuber T, Peng T, Galgiani JN, Ampel NM, Yu JJ. Glucan-Chitin Particles Enhance Th17 Response and Improve Protective Efficacy of a Multivalent Antigen (rCpa1) against Pulmonary Coccidioides posadasii Infection. Infect Immun. 2018 11; 86(11).
-
Schocker NS, Portillo S, Brito CR, Marques AF, Almeida IC, Michael K. Synthesis of Gala(1,3)Gal?(1,4)GlcNAca-, Gal?(1,4)GlcNAca- and GlcNAc-containing neoglycoproteins and their immunological evaluation in the context of Chagas disease. Glycobiology. 2016 Jan; 26(1):39-50.
-
Serna C, Lara JA, Rodrigues SP, Marques AF, Almeida IC, Maldonado RA. A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease. Vaccine. 2014 Jun 12; 32(28):3525-32.
-
Nakayasu ES, Sobreira TJ, Torres R, Ganiko L, Oliveira PS, Marques AF, Almeida IC. Improved proteomic approach for the discovery of potential vaccine targets in Trypanosoma cruzi. J Proteome Res. 2012 Jan 01; 11(1):237-46.
-
Ramey K, Eko FO, Thompson WE, Armah H, Igietseme JU, Stiles JK. Immunolocalization and challenge studies using a recombinant Vibrio cholerae ghost expressing Trypanosoma brucei Ca(2+) ATPase (TBCA2) antigen. Am J Trop Med Hyg. 2009 Sep; 81(3):407-15.
-
Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, Correa J. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine. 2004 Mar 12; 22(9-10):1320-6.
-
Igietseme JU, Eko FO, He Q, Black CM. Antibody regulation of Tcell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines. 2004 Feb; 3(1):23-34.
-
Armijos RX, Weigel MM, Romero L, Garcia V, Salazar J. Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last? J Infect Dis. 2003 Jun 15; 187(12):1959-61.
-
Armijos RX, Weigel MM, Aviles H, Maldonado R, Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis. 1998 May; 177(5):1352-7.
-
Hui GS, Nikaido C, Hashiro C, Kaslow DC, Collins WE. Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys. Infect Immun. 1996 May; 64(5):1502-9.